ArticleNew microbes and new infections2025
Species distribution, antifungal susceptibility, and clinical profiles of patients with osteoarticular fungal Infections: A retrospective study.
Article in New microbes and new infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteoarticular fungal infections (OAFIs), including fungal osteomyelitis and septic arthritis, represent uncommon but clinically significant complications in musculoskeletal care. Current management remains challenging due to limited evidence guiding antifungal selection. This study aims to characterize the epidemiological patterns, clinical features, and antifungal susceptibility profiles of OAFIs, with particular focus on the critical role of Methods: A retrospective study of patients was conducted with OAFIs treated between January 2020 and February 2024, analyzing clinical manifestations, surgical interventions, and associated risk factors. Fungal identification was performed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), followed by broth microdilution antifungal susceptibility testing for amphotericin B (AMB), fluconazole (FLC), voriconazole (VRC), and posaconazole (POS). Minimum inhibitory concentration (MIC) values were interpreted according to CLSI guidelines to determine susceptibility profiles and identify potential resistance mechanisms. Results: Sixty fungal isolates were isolated from 60 patients with OAFIs including Conclusion: We concluded that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.